Top Markets
Coin of the day
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

3378
Rangering i aksjer #13050
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and... Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Aksjekurs
$3.91
Markedsverdi
$524.79M
Endring (1 dag)
-0.71%
Endring (1 år)
-
Land
CN
Handel Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)

Kategori

Inntekter for Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Hanx Biopharmaceuticals (Wuhan) Co., Ltd. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Hanx Biopharmaceuticals (Wuhan) Co., Ltd. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH